The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy
In 2024, the EBMT activity survey surpassed one million HCTs reported since 1990, a major milestone in cellular therapy. That year, 47,204 HCTs (21,023 allogeneic, 26,181 autologous) were reported in 43,791 patients across 688 centres in 53 countries. Compared to 2023, HCT activity decreased (-1.1% overall, -3.9% autologous), while allogeneic increased ( + 2.6%) to the highest annual activity to date. CAR-T therapy reached 6,082 patients ( + 24.5% vs 2023), surpassing 20,000 since 2018. Main indications for allo-HCT were myeloid (62%), lymphoid malignancies (~24%), and non-malignant disorders (~17%). For auto-HCT were plasma cell disorders (59%), lymphomas (22%), and solid tumours (~6%). Unrelated donors (56%) increased ( + 5%), while HLA-identical siblings (25%) and haploidentical (19%) remained stable. Cord blood use continued decreasing (-6.2%). Paediatric HCT activity decreased slightly (-1.7%; -1.9% allogeneic, -1.1% autologous). CAR-T therapy expanded (lymphomas remaining the leading indication (70%), followed by multiple myeloma (18%,) and ALL (8%). Autoimmune diseases indications increased by 67%). Overall, transplant and CAR-T activity steadily increased, with pandemic-related declines mitigated by safety measures, reflecting systems resilience and variable country contributions. From 2025, the EBMT survey will capture adult and paediatric activity separately, establishing a comprehensive database to monitor trends, inform practice, define clinical needs and assess equitable access.
Authors
- A. Sureda
- Donal P. McLornan (ORCID: https://orcid.org/0000-0003-1224-091X)
- Helen Baldomero (ORCID: https://orcid.org/0000-0002-6554-483X)
- Tobias Alexander (ORCID: https://orcid.org/0000-0003-1193-0097)
- Am Risitano
- Mette D. Hazenberg (ORCID: https://orcid.org/0000-0002-5113-0249)
- Maria Ester Bernardo (ORCID: https://orcid.org/0000-0002-0099-8021)
- Marina Atlija
- Jakob R. Passweg
- Charles Crawley
- Iliana Kleovoulou
- Dina Averbuch
- Ali Bazarbachi
- Isabel Sánchez-Ortega
- Raffaella Greco (ORCID: https://orcid.org/0000-0002-6117-5328)
- Ibrahim Yakoub-Agha
- Annalisa Ruggeri (ORCID: https://orcid.org/0000-0002-7261-2765)
- Krzysztof Kalwak (ORCID: https://orcid.org/0000-0003-1174-5799)
- Fabio Ciceri (ORCID: https://orcid.org/0000-0003-0873-0123)
- Olaf Penack (ORCID: https://orcid.org/0000-0003-4876-802X)
- Emanuele Angelucci (ORCID: https://orcid.org/0000-0002-6512-6080)
Institutions
- Office of Education (US)
- Executive Office of the President (US)
- Vita-Salute San Raffaele University (IT)
- Inserm (FR)
- Hebrew University of Jerusalem (IL)
- Université de Lille (FR)
- Hadassah Medical Center (IL)
- Royal London Hospital (GB)
- University Hospital of Basel (CH)
- Wroclaw Medical University (PL)
- Humboldt-Universität zu Berlin (DE)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Lille’s Cardiology Hospital (FR)
- European Society for Blood and Marrow Transplantation (NL)
- Institut Català d'Oncologia (ES)
- Azienda Ospedaliera S.Giuseppe Moscati (IT)
- IRCCS Ospedale San Raffaele (IT)
- The San Raffaele Telethon Institute for Gene Therapy (IT)
- Ospedale Policlinico San Martino (IT)
- Amsterdam University Medical Centers (NL)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Addenbrooke's Hospital (GB)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
- University College London (GB)
- Universitat de Barcelona (ES)
- University of Amsterdam (NL)
- American University of Beirut (LB)
Publication Details
- Journal
- Bone Marrow Transplantation
- Published
- 2026-05-27
- DOI
- https://doi.org/10.1038/s41409-026-02919-9
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00